Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Dabigatran: Metabolite-Aware Assay Design
2026-08-15
Dabigatran and Pradaxa are more than direct thrombin inhibition tools: their active metabolite can materially change assay interpretation. This guide develops a metabolite-aware framework for thrombin generation, coagulation function tests, and translational anticoagulation research.
-
BPN-19186 (SKU A8959) Assay Guide
2026-08-14
This scenario-based guide explains how BPN-19186 (SKU A8959) can support more controlled viability, proliferation, and signaling-pathway experiments when solvent, dosing, and mechanistic interpretation are carefully separated. It combines product-specific handling data with the reported hepatic sEH–Nrf2–osteoclastogenesis findings while clearly distinguishing established evidence from exploratory assay recommendations.
-
Demethyleneberberine in Neurodegenerative Disease Research
2026-08-14
The 2022 review frames Demethyleneberberine (DMB), a berberine metabolite, as a potential neuroprotective molecule through coordinated effects on neuroinflammation, oxidative stress, mitochondrial dysfunction, and neuronal signaling. Its main contribution is a mechanistic synthesis linking NF-κB, MAPK, and AMPK pathways, while also identifying the limited disease-specific and experimental evidence that must be addressed in future studies.
-
Dabigatran Workflows for Thrombin Assays
2026-08-13
Dabigatran, also known as Pradaxa, provides a reversible benchmark for thrombin inhibition assays, coagulation function tests, and parent–metabolite comparisons. This practical guide emphasizes solubility control, concentration design, orthogonal readouts, and the weaker activity of dabigatran acylglucuronide.
-
YM 58483 (BTP2) for SOCE Assays
2026-08-13
YM 58483 (BTP2) links calcium-entry pharmacology to practical T-cell and fibrosis workflows. This guide covers dose planning, calcium imaging, IL-2 readouts, salivary-gland models, and troubleshooting for more interpretable SOCE experiments.
-
Minocycline HCl in Retinal Microglia Research
2026-08-12
Use Minocycline HCl as a pharmacological microglial-suppression control when testing 40-Hz flicker, amyloid-β clearance, and retinal function. This workflow connects molecular readouts such as MHC-II and Aβ burden with ERG and OKR outcomes while highlighting formulation, specificity, and interpretation safeguards.
-
Ibrexafungerp Activity Against Resistant Candida auris
2026-08-12
Wiederhold and colleagues showed that ibrexafungerp retained in vitro activity against fluconazole-resistant Candida auris and improved outcomes in a neutropenic mouse model when treatment began after infection was established. The study’s delayed-treatment design provides a useful translational framework for comparing oral glucan synthase inhibitors with echinocandin therapy in azole-resistant Candida research.
-
MK-0812 for CCR2 Monocyte Trafficking Studies
2026-08-11
MK-0812 is a selective CCR2 antagonist for connecting MCP-1-driven monocyte movement with tissue inflammation. This guide translates its whole-blood potency into practical chemotaxis, flow-cytometry, and gut–liver-axis workflows while emphasizing controls, dose selection, and troubleshooting.
-
Caspofungin Workflows for Resistant Candida
2026-08-11
Caspofungin provides a mechanism-focused benchmark for Candida susceptibility testing, delayed-treatment models, and fungal cell wall studies. This guide translates its glucan synthase activity into practical workflows, comparator designs, and troubleshooting strategies for resistant-isolate research.
-
SFI and the SRC/PI3K/AKT Pathway in Glioma
2026-08-10
This study combines network pharmacology with cell-based and mouse experiments to investigate how Shenqi Fuzheng injection suppresses glioma proliferation and migration. Its central contribution is the identification and experimental support of SRC/PI3K/AKT signaling as a mechanistic axis linking SFI exposure with cell-cycle arrest, reduced epithelial–mesenchymal transition-associated migration, and slower tumor growth.
-
2-Hydroxypropyl-β-cyclodextrin Protocol Guide
2026-08-09
2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide solubilizer for poorly water-soluble compounds, especially molecules with aromatic or phenyl groups. This dossier-based guide covers solution preparation, inclusion complex screening, QC, and limitations; it does not establish therapeutic efficacy or clinical bioavailability.
-
Cyclo (-RGDfC): An Assay Design Guide
2026-08-08
Cyclo (-RGDfC) enables controlled studies of αvβ3 integrin biology, from cell adhesion to tumor-targeting workflows. This guide connects its molecular properties with lessons from an osteosarcoma viability study to improve assay controls, interpretation, and translational relevance.
-
Anemoside B4, CD1d, and NLRP3 in Colitis
2026-08-07
This preprint identifies a macrophage-centered mechanism by which anemoside B4 attenuates DSS-induced colitis, linking CD1d to the AKT-STAT1-PRDX1-NF-κB axis and NLRP3 inflammasome activation. Its combination of NLRP3-deficient and macrophage-specific CD1d depletion models provides a useful framework for distinguishing pathway association from functional dependency in intestinal inflammation research.
-
Verapamil HCl: L-Type Calcium Channel Blocker in Translation
2026-08-07
Verapamil HCl stands out as an L-type calcium channel blocker with validated impact in bone turnover, cancer apoptosis, and inflammation models. This article guides researchers through advanced experimental workflows, highlights protocol optimizations, and translates the latest mechanistic insights—including TXNIP pathway targeting—into actionable assay strategies.
-
Dihydroquercetin Stimulates Porcine Intestinal Cell Growth v
2026-08-06
This study identifies dihydroquercetin (DHQ) as a potent enhancer of porcine intestinal epithelial cell proliferation through activation of the Wnt/β-catenin pathway. The findings provide mechanistic insight with implications for gut barrier support and cellular regeneration in the context of intestinal stress.